Greenwich, Connecticut, United States Shumway Capital is the famous VC, which was founded in 2011. The venture was found in North America in United States. The main department of described VC is located in the Greenwich.
Among the most popular portfolio startups of the fund, we may highlight Finch Therapeutics Group, Vedanta Biosciences, Artsy. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Banking, Pharmaceutical. Besides, a startup needs to be aged 11-15 years to get the investment from the fund.
The fund is constantly included in less than 2 deals per year. The real fund results show that this VC is 23 percentage points more often commits exit comparing to other companies. The common things for fund are deals in the range of 10 - 50 millions dollars. The average startup value when the investment from Shumway Capital is 100-500 millions dollars. The high activity for fund was in 2019.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Shumway Capital, startups are often financed by Thrive Capital, ZhenFund, Willett Advisors LLC. The meaningful sponsors for the fund in investment in the same round are Avenir Growth Capital, Willett Advisors LLC, Noro-Moseley Partners. In the next rounds fund is usually obtained by Symbiosis, Noro-Moseley Partners, Hatteras Venture Partners.
The fund was created by Chris Shumway. Besides them, we counted 4 critical employees of this fund in our database.
Related Funds
Funds with similar focus
| Fund Name | Location |
| CITIC Group Corporation | Beijing, Beijing, China |
| Citius | - |
| Golden Equator Capital | Central Region, Singapore, Singapore |
| Map Master | Aichi Prefecture, Japan, Nagoya |
| Peilin Nengyuan Touzi | China, Fujian, Hunan |
| Quilvest | Luxembourg, Luxembourg |
| Sandbox Insurtech Ventures | Chicago, Illinois, United States |
| Vietnam Innovative Startup Accelerator | Chicago, Illinois, United States |
| Watershed Capital | Austin, Texas, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Finch Therapeutics | $53M | 21 Aug 2019 | Massachusetts, United States | ||
Vedanta Biosciences | $18M | 13 May 2019 | Cambridge, Massachusetts, United States | ||
Elligo Health Research | $20M | 07 May 2019 | Austin, Texas, United States | ||
Elligo Health Research | $16M | 20 Mar 2018 | Austin, Texas, United States | ||
Finch Therapeutics | $36M | 01 Mar 2018 | Massachusetts, United States | ||
Elligo Health Research | 01 Mar 2016 | Austin, Texas, United States | |||
Trumid | $8M | 04 Mar 2015 | New York, United States |
– Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo technology, announced a $135m Series E financing round.
– Morgan Stanley Expansion Capital and Ally Bridge Group participated in the financing round.
– The round was also participated by Norwest Venture Partners and all major existing investors, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Sandler Merchant Banking, Shumway Capital, and Syneos Health.
– This financing allows Elligo to invest further in its technology platform and leverage data in new ways to address current challenges in the clinical trial industry.
– Vedanta Biosciences, Inc. from Cambridge, MA develops new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks.
– The company closed a $68m Series D financing.
– The round was led by affiliates of Magnetar Capital with participation from Verition Fund Management, Fosun Health Capital, co-founder PureTech Health (Nasdaq: PRTC, LSE: PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corporation, SymBiosis LLC, Shumway Capital, Health for Life Capital (Seventure Partners), and other institutional investors.
– The company plans to use the funds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrentCDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Finch Therapeutics | $53M | 21 Aug 2019 | Massachusetts, United States | ||
Vedanta Biosciences | $18M | 13 May 2019 | Cambridge, Massachusetts, United States | ||
Elligo Health Research | $20M | 07 May 2019 | Austin, Texas, United States | ||
Elligo Health Research | $16M | 20 Mar 2018 | Austin, Texas, United States | ||
Finch Therapeutics | $36M | 01 Mar 2018 | Massachusetts, United States | ||
Elligo Health Research | 01 Mar 2016 | Austin, Texas, United States | |||
Trumid | $8M | 04 Mar 2015 | New York, United States |
